ARTICLE | Clinical News
Eflornithine (DFMO): Began Phase III trial
March 1, 1999 8:00 AM UTC
Ilex Oncology Inc. (ILXO), San Antonio, Texas Product: Eflornithine (DFMO) Business: Cancer Therapeutic category: Cell proliferation Target: Ornithine decarboxylase (ODC) Description: Small molecule ...